Thalia Therapeutics, a UK biotech focused on RNA-based therapeutics and delivery systems for oncology and cardiovascular disease, has raised €3.1 million (£2.75 million) and simultaneously acquired Sanmirna Therapeutics. The deal strengthens its pipeline by adding miRisten, a clinical-stage microRNA therapeutic candidate for Acute Myeloid Leukemia.
The funding round was backed by new and existing investors, including Premier Miton. The company did not disclose the acquisition price or the round’s valuation, but the combined move signals a strategic push to consolidate early-stage assets in the RNA therapy space.
RNA therapeutics represent a rapidly growing field, with microRNA candidates gaining traction in oncology. Thalia’s focus on delivery technology addresses a key bottleneck in the sector, as getting RNA molecules to target cells efficiently remains a major challenge. The acquisition of Sanmirna provides a late-stage asset that could accelerate clinical development and attract future partnerships.
The deal highlights a trend of small biotechs using M&A to acquire de-risked clinical assets rather than developing wholly novel candidates from scratch. This approach can reduce timelines and improve chances of regulatory approval, though integrating teams and technologies poses execution risks.
Founded by a team with deep RNA biology expertise, Thalia has yet to announce a timetable for miRisten trials. Investor support from Premier Miton suggests confidence in the combined platform, but the field remains competitive with larger players like Moderna and BioNTech dominating RNA delivery innovation.
Counter-argument: The RNA therapeutics market is crowded, and microRNA-based drugs have yet to achieve broad clinical success. Thalia's ability to execute on miRisten and differentiate its delivery platform from larger rivals remains unproven, raising questions about long-term viability.